Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease

10. oktober 2013 oppdatert av: GlaxoSmithKline

Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a Plus Ribavirin

The purpose of this study is to assess the ability of eltrombopag to maintain a platelet count sufficient to facilitate initiation of antiviral therapy, to minimise antiviral therapy dose reductions and to avoid permanent discontinuation of antiviral therapy. The clinical benefit of eltrombopag will be measured by the proportion of subjects who are able to achieve a Sustained Virological Response (SVR).

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Faktiske)

687

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Australia
    • Australian Capital Territory
      • Garran, Australian Capital Territory, Australia, 2606
        • GSK Investigational Site
    • New South Wales
      • Camperdown, New South Wales, Australia, 2050
        • GSK Investigational Site
      • Randwick, New South Wales, Australia, 2031
        • GSK Investigational Site
    • Victoria
      • Fitzroy, Victoria, Australia, 3065
        • GSK Investigational Site
      • Heidelberg, Victoria, Australia, 3084
        • GSK Investigational Site
      • Melbourne, Victoria, Australia, 3168
        • GSK Investigational Site
    • Western Australia
      • Nedlands, Western Australia, Australia, 6009
        • GSK Investigational Site
  • Belgia
      • Bruxelles, Belgia, 1200
        • GSK Investigational Site
      • Edegem, Belgia, 2650
        • GSK Investigational Site
      • Gent, Belgia, 9000
        • GSK Investigational Site
      • Leuven, Belgia, 3000
        • GSK Investigational Site
  • Brasil
      • São Paulo, Brasil, 04023900
        • GSK Investigational Site
    • São Paulo
      • Campinas, São Paulo, Brasil, 13083-888
        • GSK Investigational Site
  • Canada
    • Alberta
      • Calgary, Alberta, Canada, T2N 4Z6
        • GSK Investigational Site
    • British Columbia
      • Victoria, British Columbia, Canada, V8V 3P9
        • GSK Investigational Site
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3E 3P4
        • GSK Investigational Site
    • Ontario
      • Barrie, Ontario, Canada, L4M 7G1
        • GSK Investigational Site
      • Hamilton, Ontario, Canada, L8N 4A6
        • GSK Investigational Site
      • Hamilton, Ontario, Canada, L8L 2X2
        • GSK Investigational Site
      • Ottawa, Ontario, Canada, K1N 6N5
        • GSK Investigational Site
      • Ottawa, Ontario, Canada, K1H 8L6
        • GSK Investigational Site
      • Toronto, Ontario, Canada, M5T 2S8
        • GSK Investigational Site
      • Toronto, Ontario, Canada, M5G 1X5
        • GSK Investigational Site
      • Toronto, Ontario, Canada, M5G 2C4
        • GSK Investigational Site
      • Toronto, Ontario, Canada, M6H 3M1
        • GSK Investigational Site
    • Quebec
      • Montreal, Quebec, Canada, H2X 2P4
        • GSK Investigational Site
      • Montreal, Quebec, Canada, H2X 3J4
        • GSK Investigational Site
  • Den russiske føderasjonen
      • Moscow, Den russiske føderasjonen, 129110
        • GSK Investigational Site
      • Moscow, Den russiske føderasjonen, 110020
        • GSK Investigational Site
      • Mosocow, Den russiske føderasjonen, 117593
        • GSK Investigational Site
      • Smolensk, Den russiske føderasjonen, 214018
        • GSK Investigational Site
  • Forente stater
    • Alabama
      • Birmingham, Alabama, Forente stater, 35294-0005
        • GSK Investigational Site
    • Arizona
      • Tucson, Arizona, Forente stater, 85750
        • GSK Investigational Site
    • Arkansas
      • Little Rock, Arkansas, Forente stater, 72205-7199
        • GSK Investigational Site
    • California
      • La Jolla, California, Forente stater, 92037
        • GSK Investigational Site
      • Los Angeles, California, Forente stater, 90017
        • GSK Investigational Site
      • Los Angeles, California, Forente stater, 90048
        • GSK Investigational Site
      • San Clemente, California, Forente stater, 92673
        • GSK Investigational Site
    • Colorado
      • Aurora, Colorado, Forente stater, 80045
        • GSK Investigational Site
    • Connecticut
      • New Haven, Connecticut, Forente stater, 06520
        • GSK Investigational Site
    • District of Columbia
      • Washington, District of Columbia, Forente stater, 20010
        • GSK Investigational Site
      • Washington, District of Columbia, Forente stater, 20307
        • GSK Investigational Site
    • Florida
      • Bradenton, Florida, Forente stater, 34209
        • GSK Investigational Site
      • Gainsville, Florida, Forente stater, 32610
        • GSK Investigational Site
      • Miami, Florida, Forente stater, 33136
        • GSK Investigational Site
      • Orlando, Florida, Forente stater, 32803
        • GSK Investigational Site
    • Georgia
      • Atlanta, Georgia, Forente stater, 30309
        • GSK Investigational Site
    • Hawaii
      • Honolulu, Hawaii, Forente stater, 96817
        • GSK Investigational Site
    • Kentucky
      • Louisville, Kentucky, Forente stater, 40202
        • GSK Investigational Site
    • Maryland
      • Baltimore, Maryland, Forente stater, 21202
        • GSK Investigational Site
    • Massachusetts
      • Burlington, Massachusetts, Forente stater, 01805
        • GSK Investigational Site
      • Worcester, Massachusetts, Forente stater, 01655
        • GSK Investigational Site
    • Michigan
      • Ann Arbor, Michigan, Forente stater, 48109
        • GSK Investigational Site
      • Detroit, Michigan, Forente stater, 48201
        • GSK Investigational Site
    • Mississippi
      • Jackson, Mississippi, Forente stater, 39202
        • GSK Investigational Site
    • Missouri
      • St. Louis, Missouri, Forente stater, 63110
        • GSK Investigational Site
    • New York
      • Bronx, New York, Forente stater, 10468
        • GSK Investigational Site
      • Manhasset, New York, Forente stater, 11030
        • GSK Investigational Site
      • New York, New York, Forente stater, 10021
        • GSK Investigational Site
      • Rochester, New York, Forente stater, 14642
        • GSK Investigational Site
      • Syracuse, New York, Forente stater, 13210
        • GSK Investigational Site
      • Valhalla, New York, Forente stater, 10595
        • GSK Investigational Site
    • North Carolina
      • Asheville, North Carolina, Forente stater, 28801
        • GSK Investigational Site
      • Durham, North Carolina, Forente stater, 27705
        • GSK Investigational Site
    • Oklahoma
      • Tulsa, Oklahoma, Forente stater, 74104
        • GSK Investigational Site
    • Oregon
      • Portland, Oregon, Forente stater, 97239
        • GSK Investigational Site
    • Pennsylvania
      • Hershey, Pennsylvania, Forente stater, 17033-0850
        • GSK Investigational Site
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • GSK Investigational Site
    • Tennessee
      • Jackson, Tennessee, Forente stater, 38301
        • GSK Investigational Site
      • Nashville, Tennessee, Forente stater, 37212
        • GSK Investigational Site
      • Nashville, Tennessee, Forente stater, 37203
        • GSK Investigational Site
      • Nashville, Tennessee, Forente stater, 37205
        • GSK Investigational Site
    • Texas
      • Galveston, Texas, Forente stater, 77555-0435
        • GSK Investigational Site
      • Houston, Texas, Forente stater, 77030
        • GSK Investigational Site
      • San Antonio, Texas, Forente stater, 78215
        • GSK Investigational Site
    • Virginia
      • Charlottesville, Virginia, Forente stater, 22908
        • GSK Investigational Site
      • Fairfax, Virginia, Forente stater, 22031
        • GSK Investigational Site
      • Richmond, Virginia, Forente stater, 23249
        • GSK Investigational Site
  • Frankrike
      • Besançon, Frankrike, 25030
        • GSK Investigational Site
      • Dijon cedex, Frankrike, 21019
        • GSK Investigational Site
      • Marseille, Frankrike, 13385
        • GSK Investigational Site
      • Montpellier, Frankrike, 34295
        • GSK Investigational Site
      • Nice, Frankrike, 06202
        • GSK Investigational Site
      • Pessac Cedex, Frankrike, 33604
        • GSK Investigational Site
      • Strasbourg, Frankrike, 67091
        • GSK Investigational Site
      • Toulouse, Frankrike, 31300
        • GSK Investigational Site
      • Toulouse cedex 9, Frankrike, 31059
        • GSK Investigational Site
  • Hong Kong
      • Pokfulam, Hong Kong
        • GSK Investigational Site
  • India
      • Bangalore, India
        • GSK Investigational Site
      • Chennai, India, 600 096
        • GSK Investigational Site
      • Mumbai, India, 400036
        • GSK Investigational Site
  • Israel
      • Haifa, Israel, 31096
        • GSK Investigational Site
      • Jerusalem, Israel, 91120
        • GSK Investigational Site
      • Petach Tikva, Israel, 49100
        • GSK Investigational Site
      • Safed, Israel, 13110
        • GSK Investigational Site
      • Tel Aviv, Israel, 64239
        • GSK Investigational Site
  • Italia
    • Calabria
      • Catanzaro, Calabria, Italia, 88100
        • GSK Investigational Site
    • Campania
      • Avellino, Campania, Italia, 83100
        • GSK Investigational Site
    • Emilia-Romagna
      • Bologna, Emilia-Romagna, Italia, 40138
        • GSK Investigational Site
    • Lazio
      • Roma, Lazio, Italia, 00133
        • GSK Investigational Site
    • Liguria
      • Genova, Liguria, Italia, 16132
        • GSK Investigational Site
    • Lombardia
      • Brescia, Lombardia, Italia, 25123
        • GSK Investigational Site
      • Milano, Lombardia, Italia, 20132
        • GSK Investigational Site
      • Milano, Lombardia, Italia, 20157
        • GSK Investigational Site
    • Puglia
      • Bari, Puglia, Italia, 70124
        • GSK Investigational Site
      • San Giovanni Rotondo (FG), Puglia, Italia, 71013
        • GSK Investigational Site
    • Sicilia
      • Palermo, Sicilia, Italia, 90127
        • GSK Investigational Site
  • Korea, Republikken
      • Busan, Korea, Republikken, 614-735
        • GSK Investigational Site
      • Incheon, Korea, Republikken, 400-711
        • GSK Investigational Site
      • Seoul, Korea, Republikken, 135-710
        • GSK Investigational Site
  • Nederland
      • Amsterdam, Nederland, 1081 HV
        • GSK Investigational Site
      • Nijmegen, Nederland, 6525 GA
        • GSK Investigational Site
      • Rotterdam, Nederland, 3015 CE
        • GSK Investigational Site
  • Pakistan
      • Lahore, Pakistan, 54600
        • GSK Investigational Site
      • Lahore, Pakistan, 54000
        • GSK Investigational Site
  • Polen
      • Bydgoszcz, Polen, 85-030
        • GSK Investigational Site
      • Chorzow, Polen, 41-500
        • GSK Investigational Site
      • Kielce, Polen, 25-317
        • GSK Investigational Site
      • Szczecin, Polen, 71-455
        • GSK Investigational Site
      • Wroclaw, Polen, 51-149
        • GSK Investigational Site
  • Puerto Rico
      • Ponce, Puerto Rico, 00717
        • GSK Investigational Site
      • San Juan, Puerto Rico, 00927
        • GSK Investigational Site
  • Romania
      • Bucharest, Romania, 021105
        • GSK Investigational Site
      • Constanta, Romania, 900708
        • GSK Investigational Site
  • Slovakia
      • Bratislava, Slovakia, 833 05
        • GSK Investigational Site
      • Bratislava, Slovakia, 811 07
        • GSK Investigational Site
      • Kosice, Slovakia, 041 66
        • GSK Investigational Site
      • Martin, Slovakia, 036 59
        • GSK Investigational Site
  • Spania
      • Barcelona, Spania, 08025
        • GSK Investigational Site
      • Granada, Spania, 18012
        • GSK Investigational Site
      • L'Hospitalet de Llobregat. Barcelona, Spania, 08907
        • GSK Investigational Site
      • La Coruña, Spania, 15006
        • GSK Investigational Site
      • Madrid, Spania, 28006
        • GSK Investigational Site
      • Madrid, Spania, 28007
        • GSK Investigational Site
      • Madrid, Spania, 28034
        • GSK Investigational Site
      • Madrid, Spania, 28029
        • GSK Investigational Site
      • San Sebastián, Spania, 20014
        • GSK Investigational Site
      • Sevilla, Spania, 41014
        • GSK Investigational Site
      • Valencia, Spania, 46010
        • GSK Investigational Site
  • Storbritannia
      • London, Storbritannia, NW3 2QG
        • GSK Investigational Site
      • London, Storbritannia, W2 1NY
        • GSK Investigational Site
      • Plymouth, Storbritannia, PL6 8DH
        • GSK Investigational Site
    • Lanarkshire
      • Glasgow, Lanarkshire, Storbritannia, G12 0YN
        • GSK Investigational Site
  • Taiwan
      • Kaohsiung, Taiwan, 80708
        • GSK Investigational Site
      • Taichung, Taiwan, 407
        • GSK Investigational Site
      • Tainan, Taiwan, 704
        • GSK Investigational Site
      • Taipei, Taiwan, 100
        • GSK Investigational Site
  • Thailand
      • Bangkok, Thailand, 10330
        • GSK Investigational Site
      • Bangkok, Thailand, 10700
        • GSK Investigational Site
      • Chiangmai, Thailand, 50200
        • GSK Investigational Site
      • Khon Kaen, Thailand, 40002
        • GSK Investigational Site
      • Songkla, Thailand, 90110
        • GSK Investigational Site
  • Tsjekkisk Republikk
      • Praha 4, Tsjekkisk Republikk, 140 21
        • GSK Investigational Site
      • Praha 6, Tsjekkisk Republikk, 169 02
        • GSK Investigational Site
  • Tyskland
      • Berlin, Tyskland, 13353
        • GSK Investigational Site
      • Berlin, Tyskland, 12203
        • GSK Investigational Site
    • Baden-Wuerttemberg
      • Freiburg, Baden-Wuerttemberg, Tyskland, 79106
        • GSK Investigational Site
      • Heidelberg, Baden-Wuerttemberg, Tyskland, 69120
        • GSK Investigational Site
      • Stuttgart, Baden-Wuerttemberg, Tyskland, 70197
        • GSK Investigational Site
      • Ulm, Baden-Wuerttemberg, Tyskland, 89081
        • GSK Investigational Site
    • Bayern
      • Deggendorf, Bayern, Tyskland, 94469
        • GSK Investigational Site
      • Hof/Saale, Bayern, Tyskland, 95028
        • GSK Investigational Site
      • Muenchen, Bayern, Tyskland, 81377
        • GSK Investigational Site
      • Regensburg, Bayern, Tyskland, 93053
        • GSK Investigational Site
      • Wuerzburg, Bayern, Tyskland, 97080
        • GSK Investigational Site
    • Brandenburg
      • Beeskow, Brandenburg, Tyskland, 15848
        • GSK Investigational Site
    • Hessen
      • Frankfurt, Hessen, Tyskland, 60590
        • GSK Investigational Site
      • Kassel, Hessen, Tyskland, 34127
        • GSK Investigational Site
    • Niedersachsen
      • Goettingen, Niedersachsen, Tyskland, 37075
        • GSK Investigational Site
      • Hannover, Niedersachsen, Tyskland, 30159
        • GSK Investigational Site
      • Hannover, Niedersachsen, Tyskland, 30625
        • GSK Investigational Site
    • Nordrhein-Westfalen
      • Aachen, Nordrhein-Westfalen, Tyskland, 52074
        • GSK Investigational Site
      • Bochum, Nordrhein-Westfalen, Tyskland, 44787
        • GSK Investigational Site
      • Bonn, Nordrhein-Westfalen, Tyskland, 53127
        • GSK Investigational Site
      • Dortmund, Nordrhein-Westfalen, Tyskland, 44263
        • GSK Investigational Site
      • Duesseldorf, Nordrhein-Westfalen, Tyskland, 40225
        • GSK Investigational Site
      • Essen, Nordrhein-Westfalen, Tyskland, 45122
        • GSK Investigational Site
      • Herne, Nordrhein-Westfalen, Tyskland, 44623
        • GSK Investigational Site
      • Koeln, Nordrhein-Westfalen, Tyskland, 50937
        • GSK Investigational Site
      • Leverkusen, Nordrhein-Westfalen, Tyskland, 51375
        • GSK Investigational Site
      • Muenster, Nordrhein-Westfalen, Tyskland, 48143
        • GSK Investigational Site
      • Siegen, Nordrhein-Westfalen, Tyskland, 57072
        • GSK Investigational Site
    • Rheinland-Pfalz
      • Mainz, Rheinland-Pfalz, Tyskland, 55131
        • GSK Investigational Site
    • Sachsen
      • Leipzig, Sachsen, Tyskland, 04103
        • GSK Investigational Site
      • Leipzig, Sachsen, Tyskland, 04129
        • GSK Investigational Site
    • Sachsen-Anhalt
      • Halle, Sachsen-Anhalt, Tyskland, 06120
        • GSK Investigational Site
      • Magdeburg, Sachsen-Anhalt, Tyskland, 39120
        • GSK Investigational Site
  • Ukraina
      • Donetsk, Ukraina, 83114
        • GSK Investigational Site
      • Kyiv, Ukraina, 04112
        • GSK Investigational Site
      • Kyiv, Ukraina, 01030
        • GSK Investigational Site
      • Vinnytsia, Ukraina, 21021
        • GSK Investigational Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

Male and female subjects, >18 years Evidence of chronic hepatitis C virus (HCV) infection Subjects who are appropriate candidates for peginterferon (pegIFN) and ribavirin antiviral therapy A platelet count of <75,000/mcL Haemoglobin >11.0g/dL for men or >10.0g/dL for women Absolute neutrophil count (ANC) >750/mm3 and no history of infections associated with neutropenia Creatinine clearance >50mL/minute All fertile males and females must use two forms of effective contraception between them during treatment and during the 24 weeks after treatment end Subject is able to understand, consent and comply with protocol requirements and instructions and is likely to complete the study as planned

Exclusion criteria:

Non-responders to previous treatment with pegIFN and ribavirin who failed to achieve a sustained virologic response (SVR) for reasons other than thrombocytopenia, despite an optimal course (dose and duration) of combination therapy with pegIFN and ribavirin Decompensated liver disease, e.g. Child-Pugh score >6 or history of ascites or hepatic encephalopathy or current evidence of ascites Known hypersensitivity, intolerance or allergy to interferon (IFN), ribavirin, eltrombopag or any of their ingredients Serious cardiac, cerebrovascular, or pulmonary disease that would preclude treatment with pegIFN and ribavirin

Subjects with a history of any one of the following:

Suicide attempt or hospitalisation for depression in the past 5 years Any current severe or poorly controlled psychiatric disorder

The following subjects are eligible for study participation, but must be assessed and followed (if recommended) by a mental health professional:

  • Subjects who have had a severe or poorly controlled psychiatric disorder more than 6 months ago but less than 5 years ago
  • Seizure disorder that has not been well controlled History of clinically significant bleeding from oesophageal or gastric varices Subjects with haemoglobinopathies, e.g. sickle cell anaemia, thalassemia major Any prior history of arterial or venous thrombosis AND two or more of the following risk factors: hereditary thrombophilic disorders (e.g. Factor V Leiden, antithrombin III (ATIII) deficiency, etc), hormone replacement therapy, systemic contraception (containing estrogen), smoking, diabetes, hypercholesterolemia, medication for hypertension or cancer Pre-existing cardiac disease (New York Heart Association (NYHA) Grade III/IV), or arrhythmias known to involve the risk of thromboembolic events, or corrected QT interval (QTc) >450 msec Evidence of hepatocellular carcinoma Laboratory evidence of infection with human immunodeficiency virus (HIV) or active Hepatitis B Virus (HBV) infection Any disease condition associated with active bleeding or requiring anticoagulation with heparin or warfarin Therapy with any anti-neoplastic or immuno-modulatory treatment <6 months prior to the first dose of eltrombopag Subjects who have had a malignancy diagnosed and/or treated within the past 5 years, except for subjects with localised basal or squamous cell carcinoma treated by local excision or subjects with malignancies who have been adequately treated and, in the opinion of the oncologist, have an excellent chance of cancer-free survival Pregnant or nursing women Males with a female partner who is pregnant History of alcohol/drug abuse or dependence within 6 months of the study start (unless participating in a controlled rehabilitation programme) Treatment with an investigational drug or IFN within 30 days or 5 half-lives (whichever is longer) of the screening visit History of platelet clumping that prevents reliable measurement of platelet counts History of major organ transplantation with an existing functional graft Thyroid dysfunction not adequately controlled Subjects planning to have cataract surgery Evidence of portal vein thrombosis on abdominal imaging within 3 months of the baseline visit

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase
Tidsramme: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Participants with SVR were defined as those with undetectable Hepatitis C Virus (HCV) ribonucleic acid (RNA) at 24 weeks post-completion of the treatment period of the DB Phase.
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Median blodplatetall på de angitte tidspunktene under OL-fasen
Tidsramme: OL-fase: Baseline; Dag 1; Uke 1, 2, 3, 4, 5, 6, 7, 8 og 9; Antiviral baseline (opptil uke 10); Slutt på behandling (opptil uke 48); 4-ukers oppfølging (FU) (opp til uke 62); 12-ukers FU (opp til uke 70); og 24-ukers FU (opptil uke 82)
Blod tatt fra perifere blodårer ble brukt til måling av blodplatetall. Last On Treatment-vurderingen refererer til den faktiske siste behandlingsvurderingen, ikke nødvendigvis til End of Treatment-vurderingen lagt inn av etterforskeren.
OL-fase: Baseline; Dag 1; Uke 1, 2, 3, 4, 5, 6, 7, 8 og 9; Antiviral baseline (opptil uke 10); Slutt på behandling (opptil uke 48); 4-ukers oppfølging (FU) (opp til uke 62); 12-ukers FU (opp til uke 70); og 24-ukers FU (opptil uke 82)
Tid til første dosereduksjon av Peginterferon Alfa-2a og Ribavirinterapi i DB-fasen
Tidsramme: Fra baseline opp til uke 48 eller uke 72 (for deltakere med genotype 2/3) eller opp til uke 72 (for deltakere med ikke-genotype 2/3)
Tid til første dosereduksjon ble beregnet som tidsperioden fra første dose til første dosereduksjon.
Fra baseline opp til uke 48 eller uke 72 (for deltakere med genotype 2/3) eller opp til uke 72 (for deltakere med ikke-genotype 2/3)
Gjennomsnittlig endring fra baseline i systolisk blodtrykk (SBP) og diastolisk blodtrykk (DBP) på de angitte tidspunktene under DB-fasen
Tidsramme: DB Fase: Baseline; Uke 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40 og 44; Slutt på behandling (opptil uke 48); 4-ukers oppfølging (FU) (opp til uke 52); 12-ukers FU (opp til uke 60); og 24-ukers FU (opptil uke 72)
Deltakerens blodtrykk ble målt på de angitte tidspunktene under studien. Systolisk blodtrykk er et mål på blodtrykket mens hjertet slår. Diastolisk blodtrykk er et mål på blodtrykket mens hjertet er avslappet. Gjennomsnittlig endring fra baseline ble beregnet som verdien ved de angitte tidspunktene minus verdien ved baseline.
DB Fase: Baseline; Uke 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40 og 44; Slutt på behandling (opptil uke 48); 4-ukers oppfølging (FU) (opp til uke 52); 12-ukers FU (opp til uke 60); og 24-ukers FU (opptil uke 72)
Gjennomsnittlig endring fra baseline i hjertefrekvens på de angitte tidspunktene under DB-fasen
Tidsramme: DB Fase: Baseline; Uke 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40 og 44; Slutt på behandling (opptil uke 48); 4-ukers oppfølging (FU) (opp til uke 52); 12-ukers FU (opp til uke 60); og 24-ukers FU (opptil uke 72)
Hjertefrekvensen ble målt hos deltakerne på de angitte tidspunktene. Gjennomsnittlig endring fra baseline ble beregnet som verdien ved de angitte tidspunktene minus verdien ved baseline.
DB Fase: Baseline; Uke 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40 og 44; Slutt på behandling (opptil uke 48); 4-ukers oppfølging (FU) (opp til uke 52); 12-ukers FU (opp til uke 60); og 24-ukers FU (opptil uke 72)
Gjennomsnittlig endring fra baseline i vekt på de angitte tidspunktene under DB-fasen
Tidsramme: DB Fase: Baseline; Uke 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40 og 44; Slutt på behandling (opptil uke 48); 4-ukers oppfølging (FU) (opp til uke 52); 12-ukers FU (opp til uke 60); og 24-ukers FU (opptil uke 72)
Vekten til deltakerne ble registrert på de angitte tidspunktene. Gjennomsnittlig endring fra baseline ble beregnet som verdien ved de angitte tidspunktene minus verdien ved baseline.
DB Fase: Baseline; Uke 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40 og 44; Slutt på behandling (opptil uke 48); 4-ukers oppfølging (FU) (opp til uke 52); 12-ukers FU (opp til uke 60); og 24-ukers FU (opptil uke 72)
Gjennomsnittlig endring fra baseline i kroppsmasseindeks (BMI) på de angitte tidspunktene under DB-fasen
Tidsramme: DB Fase: Baseline; Uke 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40 og 44; Slutt på behandling (opptil uke 48); 4-ukers oppfølging (FU) (opp til uke 52); 12-ukers FU (opp til uke 60); og 24-ukers FU (opptil uke 72)
BMI for deltakerne ble beregnet på de angitte tidspunktene som kroppsvekt i kilogram delt på høyde i meter i kvadrat. Gjennomsnittlig endring fra baseline ble beregnet som verdien ved de angitte tidspunktene minus verdien ved baseline.
DB Fase: Baseline; Uke 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40 og 44; Slutt på behandling (opptil uke 48); 4-ukers oppfølging (FU) (opp til uke 52); 12-ukers FU (opp til uke 60); og 24-ukers FU (opptil uke 72)
Number of Participants Whose Platelet Count Increased From a Baseline Count of <75 Gi/L to a Count Greater Than or Equal to (>=) 90 Giga (10^9) Cells Per Liter (Gi/L) During the Open-label (OL) Pre-Antiviral Treatment Phase
Tidsramme: From Baseline up to Week 9 in the OL Phase
Participants were assessed for a shift from a baseline platelet count of <75 Gi/L to a count >=90 Gi/L during the OL Phase (up to 9 weeks). Local laboratories were used for platelet function tests. Platelet counts were measured by blood draw.
From Baseline up to Week 9 in the OL Phase
Number of Participants Receiving the Indicated Doses of Eltrombopag in the OL Phase Who Initiated Antiviral Therapy (Peginterferon Alfa-2a and Ribavirin) in the DB Phase
Tidsramme: From Baseline up to Week 9 in the OL Phase
In the OL Phase, participants initially received the lowest dose of eltrombopag (25 mg QD) for 2 weeks. If after this time the platelet count was <90 Gi/L, participants underwent sequential dose escalation to the next highest dose (50 mg QD for up to 2 weeks), with further dose escalations to 75 mg QD (up to 2 weeks) and 100 mg QD (up to a maximum of 3 weeks) if platelet counts remained <90 Gi/L. Participants who achieved platelet count >=90 Gi/L on any of the eltrombopag doses in the OL Phase initiated antiviral therapy in the DB Phase.
From Baseline up to Week 9 in the OL Phase
Median Platelet Count at the Indicated Time Points During the DB Phase
Tidsramme: DB Phase: Baseline; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44; End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 52); 12-week FU (up to Week 60); and 24-week FU (up to Week 72)
Blood taken from peripheral blood vessels was used for the measurement of platelet counts.
DB Phase: Baseline; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44; End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 52); 12-week FU (up to Week 60); and 24-week FU (up to Week 72)
Number of Participants in the Indicated Categories for Minimum Platelet Count With Antiviral Therapy During the DB Phase
Tidsramme: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
The minimum platelet count with antiviral therapy was categorized as follows: <25 Gi/L; >=25 to <50 Gi/L; >=50 to <90 Gi/L; >=90 to <150 Gi/L; >=150 Gi/L to <200 Gi/L; >=200 Gi/L to <400 Gi/L; and >=400 Gi/L.
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Number of Participants With Rapid Virological Response (RVR) and Extended RVR (eRVR) During the DB Phase
Tidsramme: From Baseline up to Week 12
RVR is defined as the absence of detectable HCV RNA after 4 weeks of antiviral treatment. eRVR is defined as the absence of detectable HCV RNA after 4 weeks of antiviral treatment that persisted through Week 12.
From Baseline up to Week 12
Number of Participants With Early Virological Response (EVR) and Complete EVR (cEVR) During the DB Phase
Tidsramme: From Baseline up to Week 12
EVR is defined as a clinically significant reduction from Baseline in HCV RNA (>=2 log10 decrease in HCV RNA or undetectable HCV RNA) after 12 weeks of antiviral treatment. cEVR, a subset of EVR, is defined exclusively as undetectable HCV RNA after 12 weeks of antiviral treatment.
From Baseline up to Week 12
Number of Participants With End of Treatment Response (ETR) and Sustained Virological Response at Week 12 of Follow-up (SVR12) During the DB Phase
Tidsramme: From Baseline up to Week 36 or Week 60 (for participants with Genotype 2/3) or up to Week 60 (for participants with Non-Genotype 2/3)
ETR is defined as the absence of detectable HCV RNA at the end of antiviral treatment. SVR12 is defined as the absence of detectable HCV RNA at the end of antiviral treatment and the 12-week follow-up assessment.
From Baseline up to Week 36 or Week 60 (for participants with Genotype 2/3) or up to Week 60 (for participants with Non-Genotype 2/3)
Number of Participants in the Indicated Categories for Antiviral Therapy Dose Reductions in the DB Phase
Tidsramme: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Participants were assigned a score equal to the number of times their dose of antiviral therapy (peginterferon or ribavirin) was reduced (0=no dose reductions [DRs]; 1=one DR; 2=two DRs; 3=three DRs; >3=more than three DRs). Where possible, every effort was made to maintain the recommended dose of antiviral therapy for the treatment duration in the DB Phase. However, where dose modification of antiviral therapy was required due to safety concerns, it was performed by the Investigator as per the region-specific product labels of peginterferon and ribavirin.
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Number of Participants With the Indicated Levels of Peginterferon Dose Reductions in the DB Phase
Tidsramme: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
The assigned dose in the DB Phase of peginterferon alfa-2a was 180 micrograms (mcg). For peginterferon dose modification, downward adjustments in one level increments was considered. The lowest dose of peginterferon alfa-2a that was allowed to be administered was 45 mcg. Where dose adjustment was required for moderate to severe adverse reactions (clinical and/or laboratory), an initial dose reduction to 135 mcg was generally adequate. In some cases, a dose reduction to 90 mcg or 45mcg was necessary. Dose increases toward the original dose were considered when the adverse reaction was resolved.
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Number of Participants Who Prematurely Discontinued Antiviral Therapy in the DB Phase
Tidsramme: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
The following participants were considered to have discontinued from antiviral therapy: participants who were lost to follow-up; participants who withdrew for any reason; participants who died; participants who otherwise did not complete their planned course of antiviral therapy for any reason. The planned duration of antiviral therapy was 48 weeks for participants with Non-Genotype 2/3 and 24 or 48 weeks for participants with Genotype 2/3.
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Number of Participants (Par.) Categorized as Responders (R) and Non-responders (NR) for SVR and RVR to Antiviral Therapy in the Indicated Variants of Interleukin 28B (IL28B) (or Interferon, Lambda 3) During the DB Phase
Tidsramme: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
There are two genetic variants (rs12979860 and rs8099917) mapping near IL28B associated with both interferon-induced SVR and spontaneous HCV clearance. Genotyping of the IL28B polymorphisms (rs12979860 and rs8099917) was conducted. IL28B genotype distribution by response to antiviral therapy (SVR and RVR) for both treatment arms was assessed. The effect of genotype was tested by comparing participants that carried 2 copies of the IL28B favorable response allele versus the others (recessive model). Genotypes at rs12979860 were coded as: CC=1, CT or TT=0; rs8099917 was coded as TT=1, GT or GG=0.
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Number of Par. With the Indicated Shift From Baseline (BL) in Severity Grades for Clinical Chemistry Parameters (Calcium, Glucose [Glu.], Potassium [Pot.], and Sodium [Sod.]), Per Division of Acquired Immunodeficiency Syndrome (DAIDS) During the DB Phase
Tidsramme: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Blood samples for the assessment of clinical chemistry parameters were taken at intervals throughout the study. Participants with the worst-case shift from BL during the DB Phase are reported, per severity grades by DAIDS, for levels of calcium (low=hypocalcemia; high=hypercalcemia), glu. (low=hypoglycemia; high=hyperglycemia), pot. (low=hypokalemia; high=hyperkalemia), and sod. (low=hyponatremia; high=hypernatremia). Per the DAIDS toxicity table, the grade ranges for each parameter are as follows: Grade (G) 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters (Hemoglobin, Lymphocytes [Lym.], Total Neutrophils [Tot Neu.], and White Blood Cells [WBC]), Per DAIDS During the DB Phase
Tidsramme: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Blood samples for the assessment of hematology parameters were taken at intervals throughout the study. Participants with the worst-case shift from BL during the DB Phase are reported, per severity grades by DAIDS, for levels of hemoglobin (low=anemia), lymphocytes (low=lymphocytopenia), total neutrophils (low=neutropenia), and white blood cells (low=leukocytopenia). Per the DAIDS toxicity table, grade ranges for each parameter are as follows: Grade (G) 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Number of Participants in the Indicated Categories for Cataract Event During the DB Phase, Per Clinical Events Committee (CEC) Adjudication During the DB Phase
Tidsramme: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Ophthalmic (pertaining to eye) assessments were performed during the study. A cataract event is defined as an event ascertained to be a cataract (opacity or cloudiness of the lens of the eye, causing impairment of vision) by at least one of the CEC members (comprised of expert ophthalmologists who provided objective medical review of the blinded ophthalmic data). Per the CEC, cataract events were categorized as: (1) Cataract Progression (CP; progression of cataracts present at BL); and (2) Incident Cataract (IC; development of new cataracts). One eye=unilateral; both eyes=bilateral.
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Number of Participants Assessed as Normal and Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) at the Indicated Time Points During the DB Phase
Tidsramme: DB Phase: Antiviral BL (up to Week 10); End of Treatment (up to Week 52); and 24-week FU (up to Week 72)
Duplicate 12-lead ECGs were required at Screening/BL, Antiviral BL, and at 12 weekly intervals during the study. The investigator assigned an ECG status of normal, abnormal, CS, or NCS; a status of "abnormal" alone indicates that the investigator did not determine if ECG was CS or NCS. Normal, all ECG parameters within accepted normal ranges. Abnormal, ECG finding(s) outside of normal ranges. CS, ECG with a CS abnormality that meets exclusion criteria. NCS, ECG with an abnormality not CS or meeting exclusion criteria, per Investigator, based on reasonable standards of clinical judgment.
DB Phase: Antiviral BL (up to Week 10); End of Treatment (up to Week 52); and 24-week FU (up to Week 72)
Number of Participants With CS and NCS Change From Baseline for 12-lead ECG at the Indicated Time Points During the DB Phase
Tidsramme: End of Treatment (up to Week 52); and 24-week FU (up to Week 72)
Duplicate 12-lead ECGs were required at Screening/BL, Antiviral BL, and at 12 weekly intervals during the study. The number of participants with a CS or a NCS change from baseline in ECG status was reported, as determined by the Investigator based on a reasonable standard of clinical judgment. "Not applicable" indicates that information was not provided by the investigator on whether the change from baseline ECG was CS or NCS.
End of Treatment (up to Week 52); and 24-week FU (up to Week 72)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

GlaxoSmithKline

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. oktober 2007

Primær fullføring (Faktiske)

1. april 2011

Studiet fullført (Faktiske)

1. mai 2011

Datoer for studieregistrering

Først innsendt

13. august 2007

Først innsendt som oppfylte QC-kriteriene

13. august 2007

Først lagt ut (Anslag)

15. august 2007

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

5. november 2013

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. oktober 2013

Sist bekreftet

1. august 2012

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • TPL103922

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere